The Lasting Immunological Footprint of VITT – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Adam Kanack et al, adding:
”Platelet factor 4 antibody persistence and long-term pathogenicity in vaccine-induced immune thrombotic thrombocytopenia
In VITT patients, anti-PF4 antibodies persist as monoclonal/oligoclonal clones without epitope spreading, with one case showing platelet-activating antibodies four years post-event.”
Title: Platelet factor 4 antibody persistence and long-term pathogenicity in vaccine-induced immune thrombotic thrombocytopenia
Authors: Adam Kanack, Emily Mauch, Guillaume Roberge, Noah Splinter, Krishna Gundabolu, Geoffrey Wool, Gemlyn George, Mouhamed Yazan Abou-Ismail, Kristi Smock, David Green, Jonathan Coker, Mindy Kohlhagen, David Murray, Anand Padmanabhan

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome
-
Nov 17, 2026, 13:37Abdlemewla Ibrahim: Prasugrel vs Ticagrelor in ACS Patients Undergoing PCI
-
Nov 17, 2026, 13:30Stacy E. Croteau: Oral and Dental Care in Pediatric Patients With Bleeding Disorders
-
Nov 17, 2026, 13:19Efe Saglam: Cannabis Use and Cardiac Conduction
-
Nov 17, 2026, 10:41Elena Petkovic։ Highlights from the ISBT–WHO Plasma Management Workshop
-
Nov 17, 2026, 10:30Cheng-Hock Toh: Haematology Is Everywhere – But Is It Recognised?
-
Nov 17, 2026, 10:23Akshat Jain: The Importance of Knowing Your Sickle Cell Status
-
Nov 17, 2026, 10:12Caitlin Raymond: What Does Apheresis Really Cost?
-
Nov 17, 2026, 05:47Multidisciplinary Teams Kick Off SAHF MASAC ES 2026 with Pre-Symposium Workshops – South African Haemophilia Foundation